Madrigal pharmaceuticals reports inducement grants under nasdaq listing rule 5635(c)(4)

Conshohocken, pa., march 06, 2024 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today announced that the company granted equity awards to (i) mardi c. dier, the company's new senior vice president and chief financial officer, effective march 11, 2024 and (ii) 39 other new employees, in each case with a grant date of march 1, 2024, as equity inducement awards under the terms of the company's 2023 inducement plan. the equity awards were approved in accordance with nasdaq listing rule 5635(c)(4).
MDGL Ratings Summary
MDGL Quant Ranking